The rebate system is an important lever for ensuring the affordability of prescription medications and health care premiums for Americans. AMCP supports the use of a rebate system as one of many levers to help to control drug costs.
This JMCP article analyzes the cost-effectiveness of brexanolone compared to SSRIs for postpartum depression. Findings indicate that brexanolone may serve as a cost-effective option over SSRIs.
